CNS Drugs

Brain and Spinal Cord Atrophy in Multiple Sclerosis: Role as a Surrogate Measure of Disease Progression
pp. 427-436(10)
Author: Simon J.H.

Homocysteine Levels in Patients with Stroke: Clinical Relevance and Therapeutic Implications
pp. 437-443(7)
Authors: Hankey G.J.; Eikelboom J.W.

Aetiology and Treatment of Sleep Disturbances During Perimenopause and Postmenopause
pp. 445-452(8)
Authors: Polo-Kantola P.; Saaresranta T.; Polo O.

Combination Nicotine Replacement Therapy for Smoking Cessation: Rationale, Efficacy and Tolerability
pp. 453-467(15)
Authors: Sweeney C.T.; Fant R.V.; Fagerstrom K.O.; McGovern J.F.; Henningfield J.E.

Smoking in Patients Receiving Psychotropic Medications: A Pharmacokinetic Perspective
pp. 469-494(26)
Authors: Desai H.D.; Seabolt J.; Jann M.W.

Methylphenidate (OROSFormulation)
pp. 495-500(6)
Authors: Keating G.M.; McClellan K.; Jarvis B.

Methylphenidate (OROS Formulation): A Viewpoint by Marsha D. Rappley
pp. 501-503(3)
Author: Rappley M.D.

Methylphenidate (OROS Formulation): A Viewpoint by Christopher K. Varley
pp. 501-503(3)
Author: Varley C.K.

Methylphenidate (OROS Formulation): A Viewpoint by James M. Swanson, Marc Lerner, Kenneth Steinhoff and Sharon Wigal
pp. 501-503(3)
Authors: Swanson J.M.; Lerner M.; Steinhoff K.; Wigal S.